Impact of Low-Frequency Human Immunodeficiency Virus Type 1 Drug Resistance Mutations on Antiretroviral Therapy Outcomes.
Rachel M BurdorfShuntai ZhouClaire AmonNathan LongCollin S HillLily AdamsGerald TeghaMaganizo B ChagomeranaAllan JumbeMadalitso MaliwichiShaphil WallieYijia LiRonald SwanstromMina C HosseinipourPublished in: The Journal of infectious diseases (2024)
Using accurate NGS for DRM detection may benefit an additional 10% of patients by identifying low-frequency K103N mutations.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- hiv infected
- hepatitis c virus
- end stage renal disease
- hiv positive
- hiv aids
- hiv infected patients
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- high resolution
- mass spectrometry
- prognostic factors
- adipose tissue
- real time pcr
- patient reported outcomes
- label free
- quantum dots